Amarin Announces Notification of Patent Allowance for U.S. Application 13/417,899 Related to Combination Product of Vascepa(R) and Statin Therapy Submitted by amarin on Fri, 12/08/2017 - 04:49 Read more about Amarin Announces Notification of Patent Allowance for U.S. Application 13/417,899 Related to Combination Product of Vascepa(R) and Statin Therapy
Amarin Announces Publication of Additional Inflammatory Marker Data From MARINE and ANCHOR Phase 3 Clinical Trials in the American Journal of Cardiovascular Drugs Submitted by amarin on Fri, 12/08/2017 - 04:49 Read more about Amarin Announces Publication of Additional Inflammatory Marker Data From MARINE and ANCHOR Phase 3 Clinical Trials in the American Journal of Cardiovascular Drugs
Amarin Announces First Notification of U.S. Patent Allowance Based on ANCHOR Clinical Trial Results Submitted by amarin on Fri, 12/08/2017 - 04:49 Read more about Amarin Announces First Notification of U.S. Patent Allowance Based on ANCHOR Clinical Trial Results
Amarin Announces Market Introduction of Vascepa(R) (icosapent ethyl) Capsules for the Treatment of Very High Triglycerides (VHTG) Submitted by amarin on Fri, 12/08/2017 - 04:49 Read more about Amarin Announces Market Introduction of Vascepa(R) (icosapent ethyl) Capsules for the Treatment of Very High Triglycerides (VHTG)
Amarin Announces Notification of Two Additional Patent Allowances for U.S. Applications (13/458,496 and 13/349,157) Related to Vascepa(R) and FDA Approved MARINE Indication Submitted by amarin on Fri, 12/08/2017 - 04:49 Read more about Amarin Announces Notification of Two Additional Patent Allowances for U.S. Applications (13/458,496 and 13/349,157) Related to Vascepa(R) and FDA Approved MARINE Indication
Amarin Announces Notification of Additional U.S. Patent Allowance for U.S. Application 13/272,520 Based on ANCHOR Clinical Trial Results Submitted by amarin on Fri, 12/08/2017 - 04:49 Read more about Amarin Announces Notification of Additional U.S. Patent Allowance for U.S. Application 13/272,520 Based on ANCHOR Clinical Trial Results
Amarin Announces Notification of Patent Allowance for U.S. Application 13/614,146 Related to Vascepa(R) and FDA Approved MARINE Indication Submitted by amarin on Fri, 12/08/2017 - 04:49 Read more about Amarin Announces Notification of Patent Allowance for U.S. Application 13/614,146 Related to Vascepa(R) and FDA Approved MARINE Indication
Amarin to Present at the Leerink Swann Global Healthcare Conference 2013 Submitted by amarin on Fri, 12/08/2017 - 04:49 Read more about Amarin to Present at the Leerink Swann Global Healthcare Conference 2013
Amarin Announces Notification of Patent Allowance for U.S. Application 13/614,129 Related to Vascepa(R) and FDA Approved MARINE Indication Submitted by amarin on Fri, 12/08/2017 - 04:49 Read more about Amarin Announces Notification of Patent Allowance for U.S. Application 13/614,129 Related to Vascepa(R) and FDA Approved MARINE Indication
Amarin to Present at the CITI 2013 Global Healthcare Conference Submitted by amarin on Fri, 12/08/2017 - 04:49 Read more about Amarin to Present at the CITI 2013 Global Healthcare Conference
